How They Compare on Weight Loss When the two forms are compared, the injectable version has generally produced somewhat greater average weight loss, largely because of how steadily and completely the medicine is absorbed from a shot
[13] [16] Gallbladder disease risk is increased with GLP-1 receptor agonists, particularly at weight-loss doses and longer treatment durations
"As the science evolves, we are achieving a deeper understanding of how weight loss, and treatment with these medications, can improve outcomes across diverse patient populations with obesity." A secondary analysis of the SUMMIT trial looked at the effect of tirzepatide on cardiac structure and function in 106 patients from the main SUMMIT study with HF with preserved ejection fraction (HFpEF) and obesity
This complementary action enables greater HbA1c reductions than either agent alone, with clinical trials demonstrating additive effects on glycemic control
To help you navigate these changes, weve compiled a list of Frequently Asked Questions about the post-shortage landscape for GLP-1 medications
